摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-propyn-1-yloxy)-7-(trifluoromethyl)quinoline | 1141428-34-3

中文名称
——
中文别名
——
英文名称
4-(2-propyn-1-yloxy)-7-(trifluoromethyl)quinoline
英文别名
——
4-(2-propyn-1-yloxy)-7-(trifluoromethyl)quinoline化学式
CAS
1141428-34-3
化学式
C13H8F3NO
mdl
——
分子量
251.208
InChiKey
QTOYROFJRVGTCK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    308.0±42.0 °C(predicted)
  • 密度:
    1.314±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.27
  • 重原子数:
    18.0
  • 可旋转键数:
    2.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    22.12
  • 氢给体数:
    0.0
  • 氢受体数:
    2.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2-propyn-1-yloxy)-7-(trifluoromethyl)quinoline氯代肟基乙酸乙酯三乙胺 作用下, 以 乙醚 为溶剂, 以56%的产率得到5-[[[7-(trifluoromethyl)-4-quinolinyl]oxy]methyl]-3-isoxazolecarboxylic acid ethyl ester
    参考文献:
    名称:
    Structure−Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis
    摘要:
    Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 mu M, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 mu M concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.
    DOI:
    10.1021/jm900003c
  • 作为产物:
    描述:
    7-(三氯甲基)-4-羟基喹啉3-溴丙炔potassium carbonate 、 potassium iodide 作用下, 以 丙酮 为溶剂, 反应 2.0h, 以23%的产率得到4-(2-propyn-1-yloxy)-7-(trifluoromethyl)quinoline
    参考文献:
    名称:
    Structure−Activity Relationships for a Series of Quinoline-Based Compounds Active against Replicating and Nonreplicating Mycobacterium tuberculosis
    摘要:
    Tuberculosis (TB) remains as a global pandemic that is aggravated by a lack of health care, the spread of HIV, and the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains. New anti-TB drugs are urgently required to shorten the long 6-12 month treatment regimen and to battle drug-resistant Mtb strains. We have identified several potent quinoline-based anti-TB compounds, bearing an isoxazole containing side-chain. The most potent compounds, 7g and 13, exhibited submicromolar activity against the replicating bacteria (R-TB), with minimum inhibitory concentrations (MICs) of 0.77 and 0.95 mu M, respectively. In general, these compounds also had micromolar activity against the nonreplicating persistent bacteria (NRP-TB) and did not show toxicity on Vero cells up to 128 mu M concentration. Compounds 7g and 13 were shown to retain their anti-TB activity against rifampin, isoniazid, and streptomycin resistant Mtb strains. The results suggest that quinoline-isoxazole-based anti-TB compounds are promising leads for new TB drug development.
    DOI:
    10.1021/jm900003c
点击查看最新优质反应信息